EUCTR2014-005376-29-NL
Active, not recruiting
Not Applicable
An open-label observational phase 4 study to evaluate efficacy , safety and mucosal healing of early versus late use of vedolizumab in Crohn's disease: the LOVE-CD study (LOw countries VEdolizumab in CD study) - LOVE-CD
Academic Medical Center, Gastroenterology0 sites260 target enrollmentJanuary 8, 2015
DrugsEntyvio
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Active Crohn's disease
- Sponsor
- Academic Medical Center, Gastroenterology
- Enrollment
- 260
- Status
- Active, not recruiting
- Last Updated
- 10 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\- Established diagnosis of ileal, ileocolonic or colonic Crohn’s disease with histopathological confirmation available in the record of the patient.
- •\- Moderately to severely active CD (CDAI 220\-450\) with objective evidence of ulcerations visualized on endoscopy.
- •\- Anti\-TNF discontinued for at least 6 weeks
- •\-Age 18 to 80
- •\- GROUP 1 (EARLY CD):
- •Diagnosis of CD \< 24 months prior to enrollment
- •Demonstrated failure to respond to topical or systemic corticosteroids or intolerance to corticosteroids
- •or: need for \> 2 courses of steroids since diagnosis
- •or: steroid dependency at any dose since diagnosis
- •GROUP 2 (LATE CD)
Exclusion Criteria
- •\- Prior treatment with vedolizumab.
- •\- Contraindication for endoscopy.
- •\- History of colonic dysplasia/cancer
- •\- Presence of stoma
- •\- Received other biologics within the last 6 weeks of screening
- •\- Use of 5\-ASA or corticosteroid enemas/suppositories within 2 weeks of enrollment
- •\- Chronic hepatitis B or C infection
- •\- Evidence of or treatment for C. difficile infection or other intestinal pathogen at screening within 4 weeks prior to enrollment
- •\- Active or latent tuberculosis
- •\- Conditions which in the opinion of the investigator may interfere with the subject’s ability to comply with the study procedures.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
An open label study to Evaluate Efficacy, Safety and Mucosal Healing of early versus late use of vedolizumab in ulcerative colitis: the LOVE-UC study (LOw countries VEdolizumab in UC study) LOVE-UClcerative colitisTherapeutic area: Diseases [C] - Digestive System Diseases [C06]EUCTR2014-005443-40-NLAcademic Medical Center/ Gastroenterology120
Active, not recruiting
Phase 1
An open-label study to evaluate the efficacy, safety and the healing of the mucosa of the bowel of vedolizumab in subject with early onset of ulcerative colitis versus subject with longer exisiting ulcerative colitisEUCTR2014-005443-40-HUAcademic Medical Center, Gastroenterology120
Active, not recruiting
Phase 1
An open-label study to evaluate the efficacy, safety and the healing of the mucosa of the bowel of vedolizumab in subject with early onset of Crohn's disease versus subject with longer exisiting Crohn's diseaseEUCTR2014-005376-29-HUAcademic Medical Center, Gastroenterology260
Active, not recruiting
Phase 1
An open-label study to evaluate the effectiveness, safety and the healing of the mucosa of the bowel of vedolizumab in subject with early onset on Crohn's disease versus subject with longer exisiting Crohn's disease.Active Crohn's diseaseTherapeutic area: Diseases [C] - Digestive System Diseases [C06]EUCTR2014-005376-29-BEAcademic Medical Center, Gastroenterology260
Recruiting
Phase 4
An open-label interventional phase 4 study to evaluate efficacy , safety and mucosal healing of early versus late use of vedolizumab in Crohn's disease: the LOVE-CD study (LOw countries VEdolizumab in CD study)Crohn's diseaseInflammatory bowel disease10017969NL-OMON53012Academisch Medisch Centrum130